Introducing Dolutegravir

Treatment Horizons by Chael Needle Surpassing Expectations ViiV Healthcare introduces its first FDA-approved agent ViiV Healthcare is exclusively devoted to the treatment of HIV disease, and the...

Listen with Care

Natasha Travis, MD, helps shape the HIV learning curve for physicians and patients by Chael Needle Awarded a 2012 Minority Clinical Fellowship by the HIV Medicine...

Be Smart

In an Effort to Prevent HCV, One Campaign Is Educating Youth on Body Art Risks by Larry Buhl In the U.S., an estimated thirty-six percent of...

B Alert

Researchers explore the dangers of hepatitis B and HIV coinfection by Larry Buhl New research suggests people with chronic hepatitis B virus (HBV) infection have twice...

PrEP Math

PrEP (pre-exposure prophylaxis) is fairly new, but the HIV prevention tool is not yet having a huge impact on public health. According to the...

Pride & Ambivalence

“I love June! All of the Pride parties and events make me proud to be gay! All the cute queers to cruise!” “I hate Pride...

Cure News

News of the Day The latest reports on HIV cure research show momentum by Jeannie Wraight Here’s a look at some of the HIV cure headlines over...

Curing Hep B

C2B The success in curing hep C fuels race to cure B by Larry Buhl In 2013, a revolution happened: A drug regimen was developed that could...

Dos & Dont’s

Hep C Is Manageable—If You Know the Ins and Outs by Larry Buhl You’ve been diagnosed with Hepatitis C. Now what? First, don’t panic. Doctors agree...

Protecting the Pipeline

LifeGuide HIV drug development faces challenges by Jeannie Wraight and Mariel Selbovitz, MPH Triple and now quad drugs like Gilead’s Atripla and their new compound known...